Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
21 hedge funds and large institutions have $4.12M invested in Acer Therapeutics Inc in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
33% more call options, than puts
Call options by funds: $8K | Put options by funds: $6K
23% more capital invested
Capital invested by funds: $3.35M → $4.12M (+$766K)
13% less funds holding
Funds holding: 24 → 21 (-3)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$240K |
| 2 |
Renaissance Technologies
New York
|
+$11.1K |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.45K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.42K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$584 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$298K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$37K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$29K |
| 4 |
BlackRock
New York
|
-$3.06K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.42K |
ACER Hedge Fund Activity: Q1 2022 in Review
21 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q1 2022, worth a combined $4.12M — up 23% from $3.35M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ACER and 2 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $240K. The largest seller was Nantahala Capital Management, cutting an estimated $298K.
- 21 institutional investors held Acer Therapeutics Inc (ACER) as of Q1 2022, down from 24 in Q4 2021.
- Funds reported $4.12M of Acer Therapeutics Inc stock for Q1 2022, up 23% quarter-over-quarter.
- 2 funds opened new Acer Therapeutics Inc positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Acer Therapeutics Inc buyer in Q1 2022 was Vanguard Group, an estimated $240K added.
- The largest Acer Therapeutics Inc seller in Q1 2022 was Nantahala Capital Management, an estimated $298K sold.
Based on aggregated 13F filings for Q1 2022.